355 related articles for article (PubMed ID: 28161841)
1. Prognostic factors of first-line docetaxel treatment in castration-resistant prostate cancer: roles of neutrophil-to-lymphocyte ratio in patients from Northwestern China.
Pei XQ; He DL; Tian G; Lv W; Jiang YM; Wu DP; Fan JH; Wu KJ
Int Urol Nephrol; 2017 Apr; 49(4):629-635. PubMed ID: 28161841
[TBL] [Abstract][Full Text] [Related]
2. Association of pretreatment neutrophil-to-lymphocyte ratio (NLR) and overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with first-line docetaxel.
Nuhn P; Vaghasia AM; Goyal J; Zhou XC; Carducci MA; Eisenberger MA; Antonarakis ES
BJU Int; 2014 Dec; 114(6b):E11-E17. PubMed ID: 24529213
[TBL] [Abstract][Full Text] [Related]
3. PSA time to nadir as a prognostic factor of first-line docetaxel treatment in castration-resistant prostate cancer: evidence from patients in Northwestern China.
Wu KJ; Pei XQ; Tian G; Wu DP; Fan JH; Jiang YM; He DL
Asian J Androl; 2018; 20(2):173-177. PubMed ID: 28905815
[TBL] [Abstract][Full Text] [Related]
4. Prognostic impact of the neutrophil-to-lymphocyte ratio in men with metastatic castration-resistant prostate cancer.
Sonpavde G; Pond GR; Armstrong AJ; Clarke SJ; Vardy JL; Templeton AJ; Wang SL; Paolini J; Chen I; Chow-Maneval E; Lechuga M; Smith MR; Michaelson MD
Clin Genitourin Cancer; 2014 Oct; 12(5):317-24. PubMed ID: 24806399
[TBL] [Abstract][Full Text] [Related]
5. Severe neutropenia during cabazitaxel treatment is associated with survival benefit in men with metastatic castration-resistant prostate cancer (mCRPC): A post-hoc analysis of the TROPIC phase III trial.
Meisel A; von Felten S; Vogt DR; Liewen H; de Wit R; de Bono J; Sartor O; Stenner-Liewen F
Eur J Cancer; 2016 Mar; 56():93-100. PubMed ID: 26829012
[TBL] [Abstract][Full Text] [Related]
6. Neutrophil-to-lymphocyte ratio predicts PSA response, but not outcomes in patients with castration-resistant prostate cancer treated with docetaxel.
Sümbül AT; Sezer A; Abalı H; Köse F; Gültepe I; Mertsoylu H; Muallaoğlu S; Özyılkan Ö
Int Urol Nephrol; 2014 Aug; 46(8):1531-5. PubMed ID: 24526335
[TBL] [Abstract][Full Text] [Related]
7. Systemic immune-inflammation index predicts the combined clinical outcome after sequential therapy with abiraterone and docetaxel for metastatic castration-resistant prostate cancer patients.
Fan L; Wang R; Chi C; Cai W; Zhang Y; Qian H; Shao X; Wang Y; Xu F; Pan J; Zhu Y; Shangguan X; Zhou L; Dong B; Xue W
Prostate; 2018 Mar; 78(4):250-256. PubMed ID: 29285775
[TBL] [Abstract][Full Text] [Related]
8. Combination of circulating tumor cell enumeration and tumor marker detection in predicting prognosis and treatment effect in metastatic castration-resistant prostate cancer.
Chang K; Kong YY; Dai B; Ye DW; Qu YY; Wang Y; Jia ZW; Li GX
Oncotarget; 2015 Dec; 6(39):41825-36. PubMed ID: 26497689
[TBL] [Abstract][Full Text] [Related]
9. High neutrophil-to-lymphocyte ratio predicts poor clinical outcome in patients with castration-resistant prostate cancer treated with docetaxel chemotherapy.
Yao A; Sejima T; Iwamoto H; Masago T; Morizane S; Honda M; Takenaka A
Int J Urol; 2015 Sep; 22(9):827-33. PubMed ID: 26087772
[TBL] [Abstract][Full Text] [Related]
10. Prognostic impact of pretreatment neutrophil-to-lymphocyte ratio in castration-resistant prostate cancer patients treated with first-line docetaxel.
Buttigliero C; Pisano C; Tucci M; Vignani F; Bertaglia V; Iaconis D; Guglielmini P; Numico G; Scagliotti GV; Di Maio M
Acta Oncol; 2017 Apr; 56(4):555-562. PubMed ID: 28068151
[TBL] [Abstract][Full Text] [Related]
11. High Absolute Monocyte Count Predicts Poor Clinical Outcome in Patients with Castration-Resistant Prostate Cancer Treated with Docetaxel Chemotherapy.
Shigeta K; Kosaka T; Kitano S; Yasumizu Y; Miyazaki Y; Mizuno R; Shinojima T; Kikuchi E; Miyajima A; Tanoguchi H; Hasegawa S; Oya M
Ann Surg Oncol; 2016 Nov; 23(12):4115-4122. PubMed ID: 27364499
[TBL] [Abstract][Full Text] [Related]
12. Neutrophil-to-lymphocyte ratio as a prognostic biomarker for men with metastatic castration-resistant prostate cancer receiving first-line chemotherapy: data from two randomized phase III trials.
van Soest RJ; Templeton AJ; Vera-Badillo FE; Mercier F; Sonpavde G; Amir E; Tombal B; Rosenthal M; Eisenberger MA; Tannock IF; de Wit R
Ann Oncol; 2015 Apr; 26(4):743-749. PubMed ID: 25515657
[TBL] [Abstract][Full Text] [Related]
13. PSA time to nadir as a prognostic factor of first-line docetaxel treatment in castration-resistant prostate cancer: Multicenter validation in patients from the Chinese Prostate Cancer Consortium.
Pei X; Wu K; Sun Y; Gao X; Gou X; Xu J; Gao F; He D; Li L;
Urol Oncol; 2020 Jan; 38(1):2.e11-2.e17. PubMed ID: 31672485
[TBL] [Abstract][Full Text] [Related]
14. Baseline neutrophil-lymphocyte ratio (NLR) is associated with survival and response to treatment with second-line chemotherapy for advanced prostate cancer independent of baseline steroid use.
Lorente D; Mateo J; Templeton AJ; Zafeiriou Z; Bianchini D; Ferraldeschi R; Bahl A; Shen L; Su Z; Sartor O; de Bono JS
Ann Oncol; 2015 Apr; 26(4):750-755. PubMed ID: 25538172
[TBL] [Abstract][Full Text] [Related]
15. Oncological Outcome of Docetaxel-Based Chemotherapy for Men with Metastatic Castration-Resistant Prostate Cancer.
Bejrananda T; Pripatnanont C; Tanthanuch M; Karnjanawanichkul W
J Med Assoc Thai; 2016 Dec; 99(12):1315-21. PubMed ID: 29952517
[TBL] [Abstract][Full Text] [Related]
16. Optimal sequencing of docetaxel and abiraterone in men with metastatic castration-resistant prostate cancer.
Maughan BL; Xhou XC; Suzman DL; Nadal R; Bassi S; Schweizer MT; Antonarakis ES
Prostate; 2015 Nov; 75(15):1814-20. PubMed ID: 26306637
[TBL] [Abstract][Full Text] [Related]
17. Prognostic factors and risk stratification in patients with castration-resistant prostate cancer receiving docetaxel-based chemotherapy.
Yamashita S; Kohjimoto Y; Iguchi T; Koike H; Kusumoto H; Iba A; Kikkawa K; Kodama Y; Matsumura N; Hara I
BMC Urol; 2016 Mar; 16():13. PubMed ID: 27001073
[TBL] [Abstract][Full Text] [Related]
18. Rational indication for docetaxel rechallenge in metastatic castration-resistant prostate cancer.
Heck MM; Thalgott M; Retz M; Wolf P; Maurer T; Nawroth R; Hatzichristodoulou G; Gschwend JE; Kübler H
BJU Int; 2012 Dec; 110(11 Pt B):E635-40. PubMed ID: 22889368
[TBL] [Abstract][Full Text] [Related]
19. A multicenter, randomized clinical trial comparing the three-weekly docetaxel regimen plus prednisone versus mitoxantone plus prednisone for Chinese patients with metastatic castration refractory prostate cancer.
Zhou T; Zeng SX; Ye DW; Wei Q; Zhang X; Huang YR; Ye ZQ; Yang Y; Zhang W; Tian Y; Zhou FJ; Jie J; Chen SP; Sun Y; Xie LP; Yao X; Na YQ; Sun YH
PLoS One; 2015; 10(1):e0117002. PubMed ID: 25625938
[TBL] [Abstract][Full Text] [Related]
20. Treatment outcome of docetaxel plus prednisolone for metastatic castration-resistant prostate cancer in Korea.
Cho IC; Joung JY; Seo HK; Chung J; Park WS; Lee KH
J Cancer Res Ther; 2014; 10(2):251-7. PubMed ID: 25022374
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]